instgra tafero em 
                     INSTGRA AND 
TAFERO EM 12 MILLION
HEALTH
MONTHS PHARMACEUTICALS
DRUG PROFILE OF INSTGRA 
TAFERO EM 12 MONTHS 
TABLETS
 Instgra Tafero EM tablets are used for treatment involved in HIV-
1 infections.
Instgra tablets  are containing Dolutegravir as an active 
component; whereas Tafero EM tablets are containing Tenofovir 
Alafenamide & Emtricitabine as active ingredients.
Instgra is pharmacologically classifi ed as an integrase 
inhibitor.
Tafero EM  is pharmacologically classifi ed as nucleoside reverse 
transcriptase inhibitor.
This Instgra Tafero EM combination is approved by FDA, which 
may provide better activity against HIV-1 infections.
 Instgra Tafero EM should not have capability of curing the HIV 
infection, but it can able to reduce the development of HIV-1 
further to AIDS.
This is a fi xed dose combination of one Integrase inhibitor with 
two nucleoside reverse transcriptase inhibitors.
PRODUCT DETAILS
Brand name: Instgra Tafero EM 12 months tablets
Active components: Dolutegravir + Tenofovir 
Alafenamide & Emtricitabine
Strength: 50mg + 25mg & 200mg respectively
Pack: 30 tablets in a container of both products
Mfg: Instgra – Emcure; Tafero EM - Hetero
Category: Anti-retroviral drugs
INSTGRA TAFERO EM
PRESCRIBING INFORMATION OF 
INSTGRA TAFERO EM
The prescribing information of Instgra Tafero EM is 
used for treating the HIV 1 infection for both adults 
and pediatric weighing of at least 30kg.
Tafero EM should not be combined with protease 
inhibitors.
Tafero EM indicated in pediatric patient with weight 
of at least 25kg & below 35kg.
Drawback occurs in Tafero EM uses;
Tafero EM should not be used in pre exposure 
prophylaxis therapy to diminish the danger of 
sexually obtained HIV-1 in grown-ups at high hazard.
MECHANISM OF INSTGRA 
TAFERO EM
Instgra -  Dolutegravir is  a competit ive to virus associated to HIV 
infection.
Dolutegravir is an Integrase strand transferase inhibitor,  which is active 
against HIV type 1 infection. Dolutegravir binds to the active s ite of 
integrase enzyme, HIV enzyme that helps to transmit viral  genetic 
material  into human chromosomes.
This binding inhibit ion prevents integrase binding to retro virus DNA and 
causes blockade of strand transfer step which is required for cel l  
prol i feration process.
 Instgra helps to prevent the HIV type 1 cel l  production.
TAF   is  manufactured as prodrug, which is conversed into act ive form 
inside the body known as tenofovir.  TAF containing cel l  permeabil i ty 
activit ies, through this eff ect i t  get penetrate into the infected cel ls and 
changed over as tenofovir.
 Inside the cel ls,  tenofovir is  phosphorylated into tenofovir diphosphate by 
hydrolysis.
Tenofovir diphosphate shown anti -retroviral  activity by intercedes into 
viral  DNA and causes inhibit ion of chain formation leads to stopping the 
viral  production.
ABSORPTION
After administration, the maximum plasma 
concentration of Tafero EM;
TAF within 60 minutes; Emtricitabine occurs within 3 
hours
Dolutegravir reaches within 2 to 3 hours.
The steady state level of Dolutegravir occurs within 5 
days
The blood plasma ratio of Tafero EM;
TAF: 1.0; Emtricitabine: 0.6
DISTRIBUTION
Binding property of TAF to human plasma protein by 
80%; Emtricitabine to